{"id":47318,"date":"2022-08-16T11:01:41","date_gmt":"2022-08-16T09:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/painful-diabetic-neuropathy-drugs-market-research-report-2022-researchandmarkets-com\/"},"modified":"2022-08-16T11:01:41","modified_gmt":"2022-08-16T09:01:41","slug":"painful-diabetic-neuropathy-drugs-market-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/painful-diabetic-neuropathy-drugs-market-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Painful Diabetic Neuropathy Drugs Market Research Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2022 to 2030.\n<\/p>\n

\nThis study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.\n<\/p>\n

\nPainful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who have treated in the office sitting & sedentary lifestyle.\n<\/p>\n

\nIt typically causes burning pain, paresthesias & numbness in a stocking-glove pattern that progress from the feet & hands. Healthcare should carefully consider the patient’s goal, functional status & potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the two types of medications approved by the U.S. Food and Drug Administration for treating this disorder.\n<\/p>\n

\nPeripheral Treatment trends the market<\/strong>\n<\/p>\n

\nThe treatment includes several medications such as, Anticonvulsants, Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Opioid-like medications, Topical medications, Selective serotonin reuptake inhibitors & Opioids. The medicines inhaled in this treatment costs about a range of 8$ – 560$.\n<\/p>\n

\nThey also have adverse effect as, nausea, headache, dizziness, peripheral edema, weight gain, constipation, Diarrhea, anxiety, vomiting, Somnolence, insomnia & so on. The range of patients causing adverse effect may vary from 5 % to 60 %. Various treatments for Painful Diabetic Neuropathy but the most effective & efficient is the peripheral treatment.\n<\/p>\n

\nIncreasing Prevalence Remains the Key Impeder<\/strong>\n<\/p>\n

\nDiabetes has become one of the largest global health care diseases of the 21st century. According to the Centers for Disease Control and Prevention CDCP, the population prevalence of diabetes in the North America is approaching 10% and is increasing by 5% each year. The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014.\n<\/p>\n

\nSpread of diabetes has been emerging more rapidly in low & middle income countries than in high income countries. Approximately, 60 million people in the European Region are living with this disease, by straining the Region’s economies and health systems.\n<\/p>\n

\nPrevalence of diabetes is increasing in the European Region has reached 10-12% of the population in some of the States. This increase is strongly associated with increasing trends towards overweight and obesity, unhealthy diets, physical inactivity and socioeconomic disadvantage. This trend is significantly increasing the prevalence of diabetic Neuropathy as well.\n<\/p>\n

\nKey questions answered in this report<\/strong>\n<\/p>\n